Squarepoint
DYN icon

Squarepoint’s Dyne Therapeutics DYN Stock Holding History

Squarepoint’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15.1M Buy
834,176
+579,016
+227% +$9.98M 0.02% 849
2025
Q4 		$4.99M Buy
255,160
+207,568
+436% +$3.93M 0.01% 1453
2025
Q3 		$602K Sell
47,592
-134,148
-74% -$1.53M ﹤0.01% 3096
2025
Q2 		$1.73M Buy
181,740
+139,896
+334% +$1.54M ﹤0.01% 2204
2025
Q1 		$438K Sell
41,844
-9,772
-19% -$140K ﹤0.01% 3429
2024
Q4 		$1.22M Sell
51,616
-31,613
-38% -$935K ﹤0.01% 2874
2024
Q3 		$2.99M Buy
83,229
+38,033
+84% +$1.51M ﹤0.01% 1780
2024
Q2 		$1.59M Sell
45,196
-33,984
-43% -$988K ﹤0.01% 2214
2024
Q1 		$2.25M Buy
+79,180
New +$1.79M ﹤0.01% 2018
2023
Q3 		– Sell
-34,063
Closed -$383K – 3879
2023
Q2 		$383K Buy
34,063
+9,701
+40% +$114K ﹤0.01% 2807
2023
Q1 		$281K Buy
+24,362
New +$316K ﹤0.01% 2613
2020
Q4 		– Sell
-23,174
Closed -$468K – 2990
2020
Q3 		$468K Buy
+23,174
New +$509K 0.01% 1483

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Squarepoint's DYN Position: Q1 2026 in Review

Squarepoint increased its Dyne Therapeutics (DYN) stake by 227% in Q1 2026, buying an estimated $9.98M and bringing the position to 834,176 shares worth $15.1M. The position accounts for 0.02% of the portfolio, ranked #849.

Squarepoint first reported a position in DYN in Q3 2020 and has held it in 12 quarters since. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

  • Squarepoint held 834,176 shares of Dyne Therapeutics worth $15.1M as of Q1 2026.
  • Squarepoint bought 579,016 Dyne Therapeutics shares in Q1 2026, an estimated $9.98M.
  • Dyne Therapeutics made up 0.02% of Squarepoint's portfolio in Q1 2026, its #849 holding.
  • Squarepoint first reported a position in Dyne Therapeutics in Q3 2020 and has held it in 12 quarters since.
  • 227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.